Latest News

COVID vaccine interchangeability – what is the evidence?


The latest recommendation from the National Advisory Committee on Immunization (NACI) is that the second COVID-19 vaccination can be administered with a different vaccine product  (NACI, 1 June 2021). Consequently, people who received the AstraZeneca vaccine can be switched to an mRNA vaccine for the second dose. The recommendation was based on concerns about vaccine-induced immune thrombotic thrombocytopenia (VITT) following first and second vaccinations with viral-vector vaccines. Read More

COVID-19 mortality in MS patients: a systematic review


A systematic review of 87 studies has found that patients with multiple sclerosis have a slightly increased mortality risk from COVID-19, notably those who are older with significant disability and/or comorbidities (Barzegar et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e1001). Read More

Anti-CD20 therapies – Mechanisms of action


Provides information on CD20, binding epitopes of anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, ublituximab) and the effects of anti-CD20 MAbs in multiple sclerosis. Includes slides explaining antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

12 slides